Cancer Immunotherapy and Biomarkers

연구주제 · Oncology

참여 교수

교수	연구분야	논문
김병수	생물 및 환경	4
정상택	생물 및 환경	4

연결되는 NTIS 분류

없음

논문 (피인용 순)

연도	논문	학부 저자	피인용
2021	T‐Cell‐Derived Nanovesicles for Cancer Immunotherapy Advanced Materials	김병수	75
2021	Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects Advanced Materials	김병수	57
2024	Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment Advanced Materials	김병수	31
2022	Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes Nature Communications	정상택	19
2024	Strategies to Overcome Hurdles in Cancer Immunotherapy Biomaterials Research	김병수	18
2023	Glycan-Controlled Human PD-1 Variants Displaying Broad-Spectrum High Binding to PD-1 Ligands Potentiate T Cell Molecular Pharmaceutics	정상택	3
2025	Directed evolution–driven reprogramming of PD-L1 for compact and tunable checkpoint modulation Journal of Biological Engineering	정상택	1
2025	Directed evolution and modular integration of a high-affinity ICOS-L variant for potent T cell–mediated tumor elimination Journal of Biological Engineering	정상택	0

인접 그래프

노드 hover = 이웃 강조 · 1회 클릭 = 고정 · 고정된 노드 다시 클릭 = 페이지 이동

이 문서와 연결된 페이지

교수 2

김병수 · 정상택

논문 8

Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades · Directed evolution–driven reprogramming of PD-L1 for compact and tunab · Strategies to Overcome Hurdles in Cancer Immunotherapy · T‐Cell‐Derived Nanovesicles for Cancer Immunotherapy · Directed evolution and modular integration of a high-affinity ICOS-L v · Glycan-Controlled Human PD-1 Variants Displaying Broad-Spectrum High B · Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversin · Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macr

학문분야 1